Results 1 to 10 of about 3,509,415 (263)

Strategies for sensing neurotransmitters with responsive MRI contrast agents

Chemical Society Reviews, 2017
A great deal of research involving multidisciplinary approaches is currently dedicated to the understanding of brain function. The complexity of physiological processes that underlie neural activity is the greatest hurdle to faster advances.
Goran Angelovski, Éva Tóth
semanticscholar   +7 more sources

Bioluminescence-based high-throughput screen identifies pharmacological agents that target neurotransmitter signaling in small cell lung carcinoma. [PDF]

PLoS ONE, 2011
BACKGROUND: Frontline treatment of small cell lung carcinoma (SCLC) relies heavily on chemotherapeutic agents and radiation therapy. Though SCLC patients respond well to initial cycles of chemotherapy, they eventually develop resistance.
Ma Reina D Improgo, Christopher W Johnson, Andrew R Tapper, Paul D Gardner   +3 more
doaj   +6 more sources

Glycine – an important neurotransmitter and cytoprotective agent [PDF]

Acta Anaesthesiologica Scandinavica, 2005
Background:  Glycine, the simplest of the amino acids, is an essential component of important biological molecules, a key substance in many metabolic reactions, the major inhibitory neurotransmitter in the spinal cord and brain stem, and an anti‐inflammatory, cytoprotective, and immune modulating substance.Material and methods:  Based on available ...
Rune Gundersen, Per Vaagenes, Torbjørn Breivik, Frode Fonnum, P. K. Opstad   +4 more
openalex   +3 more sources

Nerve agent hydrolysis activity designed into a human drug metabolism enzyme. [PDF]

PLoS ONE, 2011
Organophosphorus (OP) nerve agents are potent suicide inhibitors of the essential neurotransmitter-regulating enzyme acetylcholinesterase. Due to their acute toxicity, there is significant interest in developing effective countermeasures to OP poisoning.
Andrew C Hemmert, Tamara C Otto, Roberto A Chica, Monika Wierdl, Jonathan S Edwards, Steven M Lewis, Carol C Edwards, Lyudmila Tsurkan, C Linn Cadieux, Shane A Kasten, John R Cashman, Stephen L Mayo, Philip M Potter, Douglas M Cerasoli, Matthew R Redinbo   +14 more
doaj   +16 more sources

The Relationship Between Dopamine Neurotransmitter Dynamics and the Blood-Oxygen-Level-Dependent (BOLD) Signal: A Review of Pharmacological Functional Magnetic Resonance Imaging

Frontiers in Neuroscience, 2018
Functional magnetic resonance imaging (fMRI) is widely used in investigations of normal cognition and brain disease and in various clinical applications. Pharmacological fMRI (pharma-fMRI) is a relatively new application, which is being used to elucidate
Tyler J. Bruinsma, Vidur V. Sarma, Vidur V. Sarma, Yoonbae Oh, Yoonbae Oh, Dong Pyo Jang, Su-Youne Chang, Su-Youne Chang, Greg A. Worrell, Val J. Lowe, Hang Joon Jo, Hang Joon Jo, Hoon-Ki Min, Hoon-Ki Min, Hoon-Ki Min   +14 more
doaj   +2 more sources

THE EFFECT OF THE CONVULSANT AGENT, CATECHOL, ON NEUROTRANSMITTER UPTAKE AND RELEASE IN RAT BRAIN SLICES [PDF]

British Journal of Pharmacology, 1981
The effect of catechol on uptake and K+‐stimulated release of γ‐aminobutyric acid (GABA), D‐aspartate, noradrenaline and acetylcholine has been studied in slices of cerebral cortex and thalamus. Low concentrations of catechol did not influence the uptake of any of the neurotransmitters in either brain area.
M. C. W. Minchin, Georgina Pearson
openalex   +4 more sources

Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells

mSphere, 2021
Coxiella burnetii causes the debilitating disease Q fever in humans. This infection is difficult to treat with current antibiotics and can progress to long-term, potentially fatal infection in immunocompromised individuals or when treatment is delayed.
Marissa S. Fullerton, Punsiri M. Colonne, Amanda L. Dragan, Katelynn R. Brann, Richard C. Kurten, Daniel E. Voth   +5 more
openalex   +4 more sources

Drosophila modifier screens to identify novel neuropsychiatric drugs including aminergic agents for the possible treatment of Parkinson's disease and depression. [PDF]

Molecular Psychiatry, 2014
Small molecules that increase the presynaptic function of aminergic cells may provide neuroprotection in Parkinson's disease (PD) as well as treatments for attention deficit hyperactivity disorder (ADHD) and depression.
Biedermann, T, Chou, M-T, Djapri, C, Hadi, R, Huang, B, Jang, J, Krantz, DE, Lam, HA, Lawal, HO, Lawless, GM, Maidment, NT, Roberts, L, Shahi, V, Terrell, A   +13 more
core   +3 more sources

Effects of Z-338, a novel gastroprokinetic agent, on the actions of excitatory and inhibitory neurotransmitters on neurons in area postrema

Journal of Smooth Muscle Research, 2010
We investigated the effects of the novel gastroprokinetic agent Z-338 on the actions of excitatory and inhibitory neurotransmitters on neurons in area postrema (AP). Iontophoretic applications of acetylcholine (ACh), AMPA and NMDA increased, while GABA suppressed the firing rates of AP neurons recorded by extracellular electrodes.
Hironari Akaike, I‐S Jang, Nobuaki Hori, Sachie K. Ogawa, Yushi Ito, Norio Akaike   +5 more
openalex   +4 more sources

Current and Future Treatments in Alzheimer Disease: An Update

Journal of Central Nervous System Disease, 2020
Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive research. Nowadays, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance: 3 cholinesterase inhibitors
Konstantina G Yiannopoulou, Sokratis G Papageorgiou   +1 more
doaj   +2 more sources